ERBB2 and lung adenocarcinoma: HER2 amplifications, on the other hand, have also been described as a potential mechanism of acquired resistance to EGFR TKI, as FISH analysis has revealed that HER2 was amplified in 12% of tumours with acquired resistance, versus only 1% of untreated lung adenocarcinomas [40].